Cullen Frost Bankers Inc. Trims Position in AbbVie Inc. $ABBV

Cullen Frost Bankers Inc. lessened its stake in AbbVie Inc. (NYSE:ABBV) by 4.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 365,525 shares of the company’s stock after selling 16,653 shares during the period. AbbVie accounts for about 0.9% of Cullen Frost Bankers Inc.’s portfolio, making the stock its 27th largest position. Cullen Frost Bankers Inc.’s holdings in AbbVie were worth $83,519,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the stock. Eclectic Associates Inc. ADV increased its stake in AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after buying an additional 45 shares during the period. Weil Company Inc. increased its stake in AbbVie by 2.3% in the 3rd quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock worth $469,000 after buying an additional 46 shares during the period. Hardin Capital Partners LLC increased its position in AbbVie by 1.4% during the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after purchasing an additional 46 shares during the period. Dogwood Wealth Management LLC increased its position in AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after purchasing an additional 46 shares during the period. Finally, Inlet Private Wealth LLC increased its position in AbbVie by 0.3% during the 3rd quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company’s stock valued at $3,937,000 after purchasing an additional 47 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 2.1%

ABBV stock opened at $213.77 on Wednesday. The firm has a 50 day moving average of $209.49 and a 200 day moving average of $219.84. The stock has a market capitalization of $377.69 billion, a PE ratio of 105.31, a price-to-earnings-growth ratio of 0.72 and a beta of 0.32. AbbVie Inc. has a 52 week low of $180.25 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the business earned $2.46 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were paid a $1.73 dividend. The ex-dividend date was Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is 340.89%.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by company insiders.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s neuroscience drugs boosted Q1 sales growth, with neuroscience revenue rising 26% year over year thanks to Vraylar, migraine treatments and Botox, signaling continued strength in a key growth area. Here’s How Neuroscience Drugs Boost AbbVie’s Q1 Sales Growth
• Positive Sentiment: AbbVie was highlighted in valuation-focused articles as potentially undervalued, which can support the stock by drawing attention to its earnings and dividend appeal. 3 Stocks That May Be Priced Below Their Estimated Value In May 2026
• Neutral Sentiment: AbbVie was listed among trending stocks after increased user interest on Zacks, but the coverage did not point to a new material catalyst by itself. Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
• Neutral Sentiment: Evercore ISI slightly lowered its price target on AbbVie to $235 from $236, which is a small adjustment and not a major negative signal for the stock. AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI
• Negative Sentiment: Broader pharmaceutical-policy headlines about Trump’s drug-pricing push could weigh on the sector, since lower Medicare pricing would pressure pharma margins and sentiment. Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Analyst Ratings Changes

A number of research analysts have commented on the stock. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. William Blair reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price on the stock. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a research report on Thursday, April 30th. Finally, Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.